About
Justin Kao is a partner at DFJ Growth who invests in companies transforming human health. He co-founded Helix in 2015, serving as founding CEO and later chief business officer, where he led partnerships with health systems, payers, and life sciences companies and worked on the company's COVID-19 diagnostic testing efforts. Before DFJ Growth, he was a partner at Khosla Ventures and an investor at Warburg Pincus, and earlier worked at Boston Consulting Group and Onyx Pharmaceuticals. He holds a BS in chemical engineering and MS in bioengineering from Stanford, plus a JD from Stanford Law School and an MBA from Stanford Graduate School of Business.
Invests in
AI & Machine LearningBiotechDeep TechDigital HealthHealthtech
Experience
- DFJ GrowthPartnercurrent2021 — presentSan Francisco Bay Area
- Khosla VenturesPartner2020 — 2021San Francisco Bay Area
- HelixCo-Founder and Chief Business Officer2015 — 2020San Mateo, CA
- Warburg PincusVice President, Healthcare2010 — 2015New York, San Francisco
- Onyx PharmaceuticalsIntern, Corporate Development2009
- Cooley Godward Kronish LLPSummer Associate2008
- The Boston Consulting GroupAssociate2005 — 2007
Education
- Stanford University Graduate School of BusinessMBA, Business
- Stanford Law SchoolJD, Law
- Stanford UniversityMS, Bioengineering
- Stanford UniversityBS, Chemical Engineering
Skills & more
+9 more
BiotechnologyInvestmentsStrategyCommercializationMergersLife SciencesVenture CapitalDesignMergers & Acquisitions (M&A)From Justin's professional profile.
Same school
Also attended Stanford University Graduate School of Business1,150
+ 1,144 more
Also attended Stanford Law School65
+ 59 more
Also attended Stanford University1,578
+ 1,572 more
Shared employers
Also worked at DFJ Growth14
+ 8 more
Also worked at Khosla Ventures77
+ 71 more
Also worked at Warburg Pincus61
+ 55 more
Also worked at Onyx Pharmaceuticals6
Deals · 3
Delfi Diagnostics, Inc.Board seat
via DFJ · filed Dec 2025 · $60M raise
InflammatixBoard seat
via DFJ · filed Mar 2021 · $102.4M raise
Attribution from SEC filings, press coverage, and firm rosters.


























%20(1).png)

















